Sleep Aid Options for Sleep Onset Insomnia
For sleep onset insomnia specifically, the AASM conditionally recommends triazolam, ramelteon, or zaleplon as first-line pharmacologic options when medication is indicated 1, 2.
Treatment Algorithm
First-Line Approach: Cognitive Behavioral Therapy
Before considering any medication, multicomponent CBT-I should be attempted first as it has a strong recommendation from the AASM with superior long-term efficacy, better daytime symptom improvement, and fewer side effects compared to pharmacotherapy 1. Medications should primarily be reserved for patients who:
- Cannot participate in CBT-I
- Have residual symptoms after adequate CBT-I trial
- Need temporary adjunct to CBT-I in select cases 1
Pharmacologic Options for Sleep Onset Insomnia
When medication is warranted, here are your evidence-based choices:
Recommended Agents (Conditional Recommendations)
Short-acting benzodiazepine:
- Triazolam 0.25 mg - Effective for sleep onset and middle-of-the-night insomnia with robust clinical evidence; notably does not impair psychomotor performance 2, 3
Melatonin receptor agonist:
- Ramelteon 8 mg - Targets circadian rhythm regulation; sufficient evidence specifically for sleep onset insomnia 2, 4, 5
Non-benzodiazepine hypnotic:
Alternative Options for Combined Sleep Onset AND Maintenance
If the patient also has sleep maintenance issues:
- Zolpidem 10 mg - Improves all objective sleep parameters but carries drowsiness risk (OR 1.82) 2, 6
- Eszopiclone 2-3 mg - Effective for both onset and maintenance 2
- Temazepam 15 mg - Longer-acting benzodiazepine option 2
Newer FDA-Approved Agents
Since the 2017 AASM guideline, lemborexant and daridorexant (dual orexin receptor antagonists) have been FDA-approved 1. While not specifically evaluated in the 2017 guideline, daridorexant shows promise for sleep maintenance and may have utility for onset as well 6, 5.
Agents NOT Recommended
The AASM conditionally recommends against the following due to insufficient efficacy evidence, lack of high-quality data, or safety concerns 1, 2:
- Trazodone (despite common off-label use)
- Diphenhydramine and other antihistamines
- Melatonin (over-the-counter formulations)
- Tryptophan
- Valerian
- Tiagabine
Critical Caveats
Duration considerations:
- Benzodiazepines and Z-drugs are suitable for short-term use (up to 4 weeks) 3
- Longer-term use requires careful individual risk-benefit assessment 3
- Non-nightly dosing may be appropriate for patients not requiring daily treatment 3
Common pitfall: Clinicians often prescribe trazodone off-label for insomnia, but the AASM explicitly recommends against this practice due to insufficient evidence 2, 4. While it may improve sleep when treating comorbid depression, it should not be used solely for insomnia.
Circadian considerations: If sleep onset insomnia appears related to delayed circadian rhythm (difficulty falling asleep at desired bedtime but normal sleep once achieved), consider ramelteon or bright light therapy in the morning to phase-advance the circadian system 7, 8.
Combination therapy: The 2026 AASM guideline addresses combining pharmacotherapy with CBT-I, though most evidence evaluates concurrent initiation rather than sequential addition 1.